Omeros Corporation's stock fell 19.12% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the company's marketing application for narsoplimab, a treatment for a rare transplant-related condition. This setback led to an investigation by Pomerantz LLP into potential securities fraud or unlawful practices by Omeros and its executives. The investigation aims to protect investors who suffered losses from the stock price decline following the announcement. This development raises concerns about the company's regulatory strategy and future prospects for narsoplimab.
Idaho Copper Corporation announced an $18 million public offering of common stock and warrants priced at $4.85 per share, with an additional 45-day option for over-allotments. The proceeds will fund an updated Preliminary Economic Assessment, initial...
The global neonatal infant care market, valued at $3.06 billion in 2025, is projected to grow to $5.59 billion by 2035 at a CAGR of 6.21%. Growth is driven by increasing preterm births and neonatal complications like respiratory disorders and jaundic...
The FDA has approved Casgevy, a gene therapy using CRISPR technology, for children aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This therapy modifies patients' own stem cells to increase fetal hemo...
Guggenheim Investments declared distributions for multiple closed-end funds, including Advent Convertible Income Fund and Guggenheim Strategic Opportunities Fund, with payments scheduled for July 31, 2026. These distributions may include income, capi...
AI/R Avenue Code, a subsidiary of AI/R, has achieved Google's Gemini Enterprise competency, recognizing its expertise in deploying advanced AI solutions securely in enterprises. This certification highlights their strengths in security, workflow auto...
